Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.
09:15am, Wednesday, 04'th Feb 2026
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX) , expanding its lineup of single-stock leveraged ETFs designed
CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery
08:15am, Wednesday, 04'th Feb 2026
Moderna CEO Stéphane Bancel discusses positive cancer vaccine trial results and the impact GLP-1 drugs on 'Mornings with Maria.' #foxbiusiness #morningswithmaria
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:55am, Tuesday, 03'rd Feb 2026
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know
06:51pm, Monday, 02'nd Feb 2026
Moderna (MRNA) concluded the recent trading session at $42.55, signifying a -3.45% move from its prior day's close.
Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?
10:09am, Friday, 30'th Jan 2026
Moderna, Inc. and Novavax, Inc. have transitioned from pandemic-era highs to focusing on cost reduction, pipeline development, and a path to breakeven by 2028. NVAX leverages partnerships with Sanofi
Moderna CMO Jacqueline Miller to step down
09:06am, Friday, 30'th Jan 2026
Moderna's Chief Medical Officer Jacqueline Miller, who led the development of the company's mRNA-based COVID-19 vaccine Spikevax, will step down effective March 2, the vaccine maker said on Friday.
Dr. David Berman to Join Moderna as Chief Development Officer
07:30am, Friday, 30'th Jan 2026
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer
mRNA-3927 is a strong strategic fit with Recordati's rare Metabolic portfolio Collaboration combines Moderna's expertise in mRNA technology for rare metabolic disorders with Recordati's established gl
Moderna will continue to lead clinical development and manufacturing for mRNA-3927 Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to
Moderna, Inc. $MRNA Shares Sold by Federated Hermes Inc.
04:26am, Thursday, 29'th Jan 2026
Federated Hermes Inc. decreased its stake in shares of Moderna, Inc. (NASDAQ: MRNA) by 3.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The instituti
This Stock Is Already Up 58% This Year. Is It a Buy?
08:45pm, Wednesday, 28'th Jan 2026
One of Moderna's leading drug candidates is proving highly effective in clinical trials. It could help expand Moderna's lineup and boost its financial results.
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know
06:50pm, Monday, 26'th Jan 2026
Moderna (MRNA) closed the most recent trading day at $47.99, moving 1.48% from the previous trading session.
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
07:00am, Monday, 26'th Jan 2026
CAMBRIDGE, MA / ACCESS Newswire / January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 13, 2026 to r
Last week's top large-cap gainers were led by precious-metals names and included standout moves in Venture Global, Moderna, Micron and Korea Electric.
MRNY: Jumping On Big Moderna Move
10:09pm, Thursday, 22'nd Jan 2026
YieldMax MRNA Option Income Strategy ETF has rebounded sharply from historic lows, driven by positive catalysts in underlying Moderna. MRNY's distributions have increased alongside MRNA's share price
